Diagnosis
Tuberculosis
A bacterial infection that can spread through the lymph nodes and bloodstream to any organ in your body.
Etiology
Cause
Mycobacterium tuberculosis is the predominant human pathogen
Other: M bovis, M africanum, and M canetii
Pathophysiology [hsn]
Spread most commonly by airborne droplet (rarely ingestion of contaminated milk)
Slow-growing intracellular pathogens --> subacute and progressive disease
Visible growth on solid media: 3 to 8 weeks (diagnostic challenge)
Genetic variability --> differences in virulence:
May remain dormant within infected cells --> may or may not cause disease
90% develop latent infection
Weaken immune system (HIV/AIDS or elderly) --> TB bacteria can become active
The bacilli may escape immunologic controls and disseminate lymphohematogenously within the lung and to virtually any other organ and cause granuloma --> caseation tissue necrosis
Clinical manifestation:
Most often found in the lungs: cough, fever, weight loss, night sweats, and malaise
Most common extrapulmonary dissemination: pleura, lymph nodes, kidneys, long bones, vertebrae, and meninges
Clinical variations:
Primary TB: Pulmonary infiltrate or atelectasis, lymphadenopathy, rarely miliary pattern (progressive primary disease)
Post-primary TB (reactivation and reinfection): Patchy consolidation, cavitation
HIV-TB coinfection: Mediastinal lymphadenopathy and extrapulmonary disease
Chronic TB: Cavitation, fibrosis, bronchiectasis, bronchopleural fistula
Risk factors
Tobacco use
Excessive alcohol use
Immunocompromised state:
Immune senescence of older age
Genetic diseases causing immunodeficiency
Human immunodeficiency virus (HIV)
Transplantation
Prolonged corticosteroid use
Cytoreductive chemotherapy
Tumor necrosis factor (TNF) antagonists
Malnutrition
Diabetes
Complications [hsn]
Septic shock
Airway obstruction
Pneumonia, bronchiectasis, empyema, hemoptysis
Broncho-pleural fistula
Meningitis
Osteomyelitis
Peritonitis
Renal abscess
Infertility
Drug toxicity: Hepatitis, peripheral neuropathy, ocular toxicity, rash, cranial nerve VIII dysfunction, renal failure, GI side effects, myaliga, arthralgia, anxiety, confusion, psychosis
Epidemiology
Incidence per 100.000 [hsn][pca][sia][hh3][wci]
Symptoms & findings
Symptoms
Anorexia, Bronchorrhea, Chills, Cough, Decreased consciousness, Distant heart sounds, Dyspnea, Fatigue, Fever, Headache, Hemoptysis, Hepatomegaly, Lymphadenopathy, Malaise, Nail clubbing, Night sweats, Pallor, Pyuria, Splenomegaly, Weakness, Weight loss
Clinical findings
Anemia, Ascites, Decreased Albumin, Elevated Sedimentation Rate, Lymphocytopenia, Mediastinal lymphadenopathy, Necrotizing granuloma, Pericardial effusion, Pleural effusion
Anamneses
None listed.
Localized findings
Approach
Blood test
Blood gas
Sputum culture: Acid-fast bacilli
Blood culture: 2 to 8 weeks for visible growth of acid-fast bacilli
Urine culture
Fluorescence microscopy: Acid-fast bacilli
Sputum cytology
Laryngeal swab
Tuberculin skin test (Mantoux skin test): diagnostic and predictive limitations [hsn]
Interferon-Gamma Release Assay (IGRA): diagnostic and predictive limitations
PCR: improved diagnostic accuracy but inaccessible in many high-prevalence regions
Chest X-ray
Bronchoscopy
Bronchoalveolar lavage
Biopsy
HIV serology
Lumbar puncture
CT
MR
Echocardiography
Treatment
Anti-TB regimens vary depending on: [hsn]
The stage and anatomic location
The immune status and age of the host
The presence of comorbidities
Drug toxicities (hepatitis, neuropathy, ocular, rash, kidney, myalgia, anxiety)
Resistance patterns of the bacterium
Profylaxis: Bacille Calmette-Guerin (BCG) Vaccine
Latent infection: weekly isoniazid plus rifampin for 3 months
Active Tuberculosis Infection - 4 drugs: isoniazid, rifampin, ethambutol, and pyrazinamide
Initial intensive bactericidal phase: 8 weeks of daily isoniazid, rifapentine, pyrazinamide, and moxifloxacin
Continuation phase sterilizes slowly replicating and dormant tubercle bacilli: 9-16 weeks of daily rifapentine, isoniazid, and moxifloxacin
Drug-Resistant Tuberculosis: Extended period (18 to 21 months) with delamanid, bedaquiline, pretomanid, linezolid, amoxicillin-clavulanate, meropenem-clavulanate, imipenem-cilastatin, cotrimoxazole, and macrolides
Differential diagnoses
Actinomycosis, Acute respiratory distress syndrome, Adrenal insufficiency, Albuminuria, Alcoholism, Anorexia nervosa, Ascites, Aspergillosis, Blastomycosis, Bone marrow failure, Bronchiectasis, Bronchitis, Cardiac tamponade, Cat scratch disease, Cerebral venous sinus thrombosis, Chronic granulomatous disease, Colorectal cancer, COPD, Crohn disease, Cytomegalovirus, Diabetes mellitus, Disseminated intravascular coagulation, Encephalitis, Endocarditis, Eosinophilic granuloma, Eosinophilic pneumonia, Epididymal tuberculosis, Erythema induratum, Erythema nodosum, Fever of unknown origin, Fungal infection, Hidradenitis suppurativa, Histoplasmosis, HIV, Hyponatremia, Influenza, Lactic acidosis, Leishmaniasis, Leprosy, Leukemia, Lung abscess, Lung cancer, Lymphoma, Measles, Meningitis, Mycobacterial infection, Nocardiosis, Pancreatic abscess, Pericarditis, Pneumoconiosis, Pneumocystis jiroveci pneumonia, Pneumonia, Polyarteritis nodosa, Pott disease, Pulmonary alveolar microlithiasis, Renal cell carcinoma, Rheumatoid arthritis, Sarcoidosis, Silicosis, Spontaneous bacterial peritonitis, Squamous cell carcinoma, Stroke, Syphilis, Syringoma, Systemic lupus erythematosus, Tularemia, Ulcerative colitis, Wegener's granulomatosis
References
[1] Tobin EH, Tristram D. Tuberculosis Overview. Updated 2024 Dec 22: https://www.ncbi.nlm.nih.gov/books/NBK441916/
[2] WHO: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2023/tb-disease-burden/1-1-tb-incidence (07.07.2025)
[3] WHO: https://data.who.int/indicators/i/13B4226/C288D13 (07.07.2025)
[4] https://www.cdc.gov/tb-surveillance-report-2023/tables/table-6.html (07.07.2025)
[5] Yang H, Ruan X, Li W, Xiong J, Zheng Y. Global, regional, and national burden of tuberculosis and attributable risk factors for 204 countries and territories, 1990-2021: a systematic analysis for the Global Burden of Diseases 2021 study. BMC Public Health. 2024 Nov 11;24(1):3111.
[6] http://emedicine.medscape.com/article/157325 (2014-01-21); [Medscape]
[7] http://emedicine.medscape.com/article/230802 (2014-01-02); [Medscape]